Market Place
Sourcing Support
MoonLake Starts Phase 3 IZAR Program of Sonelokimab in PsA
13 Nov 2024 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics Q3 2024 Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
MoonLake To Host Capital Markets Update September 11
09 Sep 2024 //
GLOBENEWSWIRE
MoonLake Reports Q2 2024 Results, Announces September 11 Market Update
07 Aug 2024 //
GLOBENEWSWIRE
MoonLake Gets Regulatory Feedback On Sonelokimab Phase 3 For Psoriatic Arthritis
10 Jun 2024 //
GLOBENEWSWIRE
MoonLake Starts Sonelokimab Phase 3 In Hidradenitis Suppurativa
16 May 2024 //
GLOBENEWSWIRE
MoonLake Reports Q1 2024 Results And Business Update
07 May 2024 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics Partners with Komodo Health
10 Apr 2024 //
GLOBENEWSWIRE
MoonLake outlines more data in psoriatic arthritis
12 Mar 2024 //
ENDPTS
MoonLake announces significant improvements with Nanobody® sonelokimab
10 Mar 2024 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results
29 Feb 2024 //
PRESS RELEASE
MoonLake Announces Positive Feedback on Regulatory Path for the Phase 3 of SLK
26 Feb 2024 //
GLOBENEWSWIRE
Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake
21 Feb 2024 //
YAHOO FINANCE
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
MoonLake`s credibility takes another hit with mid-stage study spin job
07 Nov 2023 //
STAT NEWS
MoonLake announces landmark Phase 2 results for Nanobody sonelokimab
05 Nov 2023 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics announces full dataset from its 24-week MIRA trial
15 Oct 2023 //
GLOBENEWSWIRE
MoonLake presents positive 12-week data from the Phase 2 MIRA trial
11 Oct 2023 //
GLOBENEWSWIRE
Phase 2 MIRA primary analysis trial results for MoonLake`s Nanobody sonelokimab
04 Oct 2023 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics to host Capital Markets Day on Monday, September 11
06 Sep 2023 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
MoonLake completes randomization ahead of schedule for Ph 2 in active PsA
25 Jul 2023 //
GLOBENEWSWIRE
MoonLake’s immunology drug gets help of investment bankers for potential sale
17 Jul 2023 //
ENDPTS
MoonLake Immunotherapeutics Announces Pricing of $400 Million
28 Jun 2023 //
GLOBENEWSWIRE
MoonLake Announces Pricing of $400 Million Upsized Public Offering
28 Jun 2023 //
PRESS RELEASE
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
26 Jun 2023 //
PRESS RELEASE
MoonLake`s IL-17 drug wins ‘meet or beat’ trial vs. competition
26 Jun 2023 //
FIERCE BIOTECH
MoonLake achieves landmark milestone +ve Ph2 results for Nanobody® sonelokimab
25 Jun 2023 //
GLOBENEWSWIRE
Barclays starts Moonlake Immunotherapeutics at equal weight rating
15 Jun 2023 //
SEEKING ALPHA
MoonLake Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics and SHL Medical collaborate
03 May 2023 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics to host Capital Markets Day
19 Apr 2023 //
GLOBENEWSWIRE
MoonLake Reports Fourth Quarter and Year-End 2022 Financial Results
20 Mar 2023 //
GLOBENEWSWIRE
MoonLake completes patient enrollment in PII trial of the Nanobody sonelokimab
02 Feb 2023 //
GLOBENEWSWIRE
MoonLake screens first patient in Phase 2 study of the Nanobody sonelokimab
14 Dec 2022 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody
26 Sep 2022 //
PRESS RELEASE
MoonLake signs development and manufacturing agreement with Vetter Pharma
26 Jul 2022 //
GLOBENEWSWIRE
MoonLake Immunotherapeutics (MLTX) Stock: Why It Increased 4.63% Today
22 Jul 2022 //
PULSE2
Why MoonLake Immunotherapeutics Stock Shot Up 41.1% on Tuesday
31 May 2022 //
MOTLEY FOOL
MoonLake Immunotherapeutics starts PII trial of the Nanobody Sonelokimab
12 May 2022 //
GLOBENEWSWIRE
MoonLake Announces Closing of Business Combination with Helix Acquisition Corp.
05 Apr 2022 //
GLOBENEWSWIRE
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
16 Nov 2021 //
FIERCEBIOTECH
Blade runs to Wall St. at $353M SPAC deal for 2 trials in 2022
09 Nov 2021 //
BIOSPACE
